Sponsored By:

4 Biotechnology Stocks to Sell Now

CDXS, PGNX, NYMX, ONTY slump in weekly rankings

   

The ratings of four Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Codexis (NASDAQ:CDXS) earns a F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Codexis is a developer of proprietary biocatalysts, which are enzymes or microbes that initiate or accelerate chemical reactions. The stock also earns F’s in Portfolio Grader’s specific subcategories of Earnings Revisions, Equity, Cash Flow, and Sales Growth. To get an in-depth look at CDXS, get Portfolio Grader’s complete analysis of CDXS stock.

Progenics Pharmaceuticals (NASDAQ:PGNX) experiences a ratings drop this week, going from last week’s D to a F. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The stock price has fallen 32.1% over the past month, worse than the 1.7% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

The rating of Nymox Pharmaceutical (NASDAQ:NYMX) declines this week from a D to a F. Nymox Pharmaceutical is engaged in therapeutics in development for enlarged prostate, E. coli, Alzheimer’s disease and other indications and diagnostics for tobacco exposure, Alzheimer’s disease and other conditions. For a full analysis of NYMX stock, visit Portfolio Grader.

Oncothyreon (NASDAQ:ONTY) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Oncothyreon is a biotechnology company that develops therapeutic approaches to cancer management. The trailing PE Ratio for the stock is 516.00. Over the last month, the price of ONTY has declined 2.5%. To get an in-depth look at ONTY, get Portfolio Grader’s complete analysis of ONTY stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2012/10/4-biotechnology-stocks-to-sell-now-cdxs-pgnx-nymx/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.